Proteinuria - Pipeline Review, Q2 2011

Description: Proteinuria - Pipeline Review, Q2 2011

Summary

Global Markets Direct's, 'Proteinuria - Pipeline Review, Q2 2011', provides an overview of the Proteinuria therapeutic pipeline. This report provides information on the therapeutic development for Proteinuria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Proteinuria. 'Proteinuria - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Proteinuria.
- A review of the Proteinuria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Proteinuria pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Proteinuria.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Proteinuria pipeline depth and focus of Proteinuria therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Proteinuria Overview
Therapeutics Development
An Overview of Pipeline Products for Proteinuria
Proteinuria Therapeutics under Development by Companies
Proteinuria Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Proteinuria Therapeutics - Products under Development by Companies
Proteinuria Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Proteinuria Therapeutics Development
Novartis AG
Exelixis, Inc.
InVasc Therapeutics, Inc.
Proteinuria - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Sitaxsentan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BQ-123 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tacrolimus + Prednisolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pentoxifylline + Enalapril + Losartan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XL784 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Imidapril - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Adalimumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Colchicine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pioglitazone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aliskiren + Losartan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INV-141 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INV-144 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pioglitazone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pirfenidone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Proteinuria Therapeutics – Drug Profile Updates
Proteinuria - Featured News
Dec 16, 2010: Evolva Begins Multiple Ascending Dose Study With EV-077
Jan 03, 2008: GSK Does Not Option XL784 for Further Development
Nov 02, 2007: Phase II Trial Results for Exelixis’ XL784 Presented at the 2007 American Society of Nephrology Conference
Mar 27, 2006: Exelixis Initiates Phase II Clinical Program for XL784
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Proteinuria, Q2 2011
Products under Development for Proteinuria – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Early Clinical Stage Development, Q2 2011
Comparative Analysis by Pre-Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Novartis AG, 2011
Exelixis, Inc., 2011
InVasc Therapeutics, Inc., 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Proteinuria Therapeutics – Drug Profile Updates

List of Figures
Number of Products under Development for Proteinuria, Q2 2011
Products under Development for Proteinuria – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Early Clinical Stage Products, Q2 2011
Pre-Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011

Ordering:
Order Online - http://www.researchandmarkets.com/reports/1816179/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Proteinuria - Pipeline Review, Q2 2011
Web Address: http://www.researchandmarkets.com/reports/1816179/
Office Code: SCD21WQU

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>□ USD 500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>□ USD 1000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>□ USD 1500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: __________________________________________ Last Name: __________________________________________
Email Address: * __________________________________________
Job Title: __________________________________________
Organisation: __________________________________________
Address: __________________________________________
City: __________________________________________
Postal / Zip Code: __________________________________________
Country: __________________________________________
Phone Number: __________________________________________
Fax Number: __________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World